Pembrolizumab Active in Mucosal Melanoma in KEYNOTE Studies

Source: The ASCO Post, April 2017

Three clinical trials of the immunotherapy pembrolizumab ­(Keytruda) have shown that it is active against a rare subtype of skin cancer, mucosal melanoma. The findings were presented by Butler et al at the 2017 European Cancer Congress (ECCO).1 Mucosal melanoma has often been excluded from immunotherapy treatments for the disease. Mucosal melanoma occurs in the moist surfaces that line the body’s cavities, such as the airways, digestive tract, and genitourinary tracts; there is no known cause. It makes up about 1% of all melanomas and has a poor prognosis, usually because of late diagnosis—the majority of patients with metastatic disease survive for less than 1 year on conventional treatments.

Reporting the results from three trials of pembrolizumab for patients with advanced melanoma, Marcus Butler, MD, a medical oncologist at the Princess Margaret Cancer Centre, Toronto, told ECCO 2017 that 84 of the 1,567 patients in the KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006 studies had advanced mucosal melanoma.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories